NewAmsterdam Pharma Files 8-K on Shareholder Votes & Exhibits
Ticker: NAMSW · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1936258
| Field | Detail |
|---|---|
| Company | Newamsterdam Pharma CO N.V. (NAMSW) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
Related Tickers: NAP
TL;DR
NAP stock: 8-K filed June 5th covering shareholder votes, other events, and financials.
AI Summary
On June 5, 2024, NewAmsterdam Pharma Company N.V. filed an 8-K report detailing the submission of matters to a vote of security holders, other events, and financial statements and exhibits. The filing also confirms the company's principal executive offices are located at Gooimeer 2-35, Naarden, The Netherlands.
Why It Matters
This filing provides updates on corporate actions and financial reporting for NewAmsterdam Pharma, which could impact investor decisions and regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate events and financial information, not indicating any immediate operational or financial distress.
Key Players & Entities
- NewAmsterdam Pharma Company N.V. (company) — Registrant
- June 5, 2024 (date) — Date of earliest event reported
- Gooimeer 2-35, Naarden, The Netherlands (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not elaborated in the provided text.
What 'Other Events' are reported in this 8-K filing?
The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided excerpt.
What is the significance of the 'Financial Statements and Exhibits' section?
This section indicates that financial statements and supporting exhibits are being filed, which are crucial for investors to assess the company's financial health.
When was NewAmsterdam Pharma Company N.V. incorporated or organized?
The filing states the company is incorporated in 'The Netherlands' and its fiscal year ends on December 31st, but the exact incorporation date is not specified in this excerpt.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to 'PHARMACEUTICAL PREPARATIONS'.
Filing Stats: 850 words · 3 min read · ~3 pages · Grade level 9.5 · Accepted 2024-06-07 16:15:59
Filing Documents
- d837571d8k.htm (8-K) — 44KB
- 0001193125-24-157374.txt ( ) — 203KB
- nams-20240605.xsd (EX-101.SCH) — 3KB
- nams-20240605_def.xml (EX-101.DEF) — 14KB
- nams-20240605_lab.xml (EX-101.LAB) — 23KB
- nams-20240605_pre.xml (EX-101.PRE) — 15KB
- d837571d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 10.1 License Agreement, dated June 23, 2022, between A. Menarini International Licensing S.A. and NewAmsterdam Pharma B.V. (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form F-4 (File No. 333-266510), filed with the SEC on October 13, 2022). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: June 7, 2024